Covered recipient · General Payments record
ALLISON WADE THOMPSON
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2023–2024
$281.69
- Reported across 21 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $250.08 | 19 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $180.03 | 15 |
| VIVUS LLC | $55.20 | 3 |
| Currax Pharmaceuticals LLC | $14.85 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (19)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Currax Pharmaceuticals LLC | $14.85 | 04/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1089517318 | CMS |
| Novo Nordisk Inc | $6.81 | 01/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108573418 | CMS |
| Novo Nordisk Inc | $15.09 | 01/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108567107 | CMS |
| Novo Nordisk Inc | $8.94 | 03/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108565585 | CMS |
| Novo Nordisk Inc | $7.64 | 04/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108570438 | CMS |
| Novo Nordisk Inc | $19.50 | 04/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108569556 | CMS |
| Novo Nordisk Inc | $13.64 | 05/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108569007 | CMS |
| Novo Nordisk Inc | $7.91 | 06/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108569500 | CMS |
| Novo Nordisk Inc | $9.39 | 06/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108566405 | CMS |
| Novo Nordisk Inc | $5.30 | 06/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108566337 | CMS |
| Novo Nordisk Inc | $9.40 | 07/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108565487 | CMS |
| Novo Nordisk Inc | $13.87 | 09/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108564619 | CMS |
| Novo Nordisk Inc | $22.54 | 09/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108570986 | CMS |
| Novo Nordisk Inc | $10.00 | 09/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108570728 | CMS |
| Novo Nordisk Inc | $19.14 | 10/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108570636 | CMS |
| Novo Nordisk Inc | $10.86 | 10/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108572376 | CMS |
| VIVUS LLC | $15.65 | 03/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1129421501 | CMS |
| VIVUS LLC | $22.13 | 05/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1129421503 | CMS |
| VIVUS LLC | $17.42 | 09/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1129421505 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2023, 2024
- Source files
- Dataset page · Bulk file · PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.